Back to search

Italy· 049286026

FINTEPLA*os soluz 120 ml 2,2 mg/ml + 1 adattatore per flacone + 2 sir 3 ml + 2 sir 6 ml

A fenfluramine product containing fenfluramina, registered in Italy by UCB PHARMA S.A., on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC N03AX26

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedFINTEPLA*os soluz 120 ml 2,2 mg/ml + …ATCN03AX26REGISTER NO.049286026PACKS LISTED1CHECKEDJune 4, 2026

Where it is registered

Fenfluramine is registered in 11 of 19 countries.

Countries holding a registration under ATC N03AX26 (fenfluramine), each read from that country’s own register.

  • This record: Italy
  • 8 of them publish a price we can compare per daily dose

Fenfluramine · ATC N03AX26

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Active substance
Fenfluramina
Manufacturer
UCB PHARMA S.A.
Country
Italy (IT)
ATC code
N03AX26
ATC class
Fenfluramine
Defined daily dose
8 mg, O
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    049286026
    FINTEPLA*os soluz 120 ml 2,2 mg/ml + 1 adattatore per flacone + 2 sir 3 ml + 2 sir 6 ml
    EUR 3035.63

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

349 interactions on record for fenfluramine.

Graded by severity as the source publishes them — 85 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fenfluramine · interactions on record

349 records

  • 85 severe
  • 260 moderate
  • 4 minor

Most severe, free to view

  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • PalonosetronA04AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fenfluramine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fenfluramine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fintepla
  • Liechtenstein · Fintepla
  • Norway · Fintepla

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/28c71e97-88fc-4eaa-b051-e9f6a5f0434e
GET /v1/drugs/28c71e97-88fc-4eaa-b051-e9f6a5f0434e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 3035.63,
  "source": "aifa",
  "currency": "EUR",
  "strength": "FENFLURAMINA 120 ML 2,2 MG/ML USO ORALE",
  "substance": "Fenfluramina",
  "equivalence_group": "MCH",
  "transparency_flag": null
}

See everything about fenfluramine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.